Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial

详细信息    查看全文

• 作者：Farideh Sharifipour ; Mohammadreza Razzaghi ; Alireza Ramezani…
• 关键词：Diabetic macular ischemia ; Enalapril ; Ischemic maculopathy ; Oxygen therapy
• 刊名：International Ophthalmology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：36
• 期：2
• 页码：225-235
• 全文大小：513 KB
• 参考文献：1.Ciulla TA, Amador AG, Zinman B (2003) Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26:2653–2664CrossRef PubMed
  2.Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116:1142–1150. doi:10.​1016/​j.​ophtha.​2009.​01.​011 CrossRef PubMed
  3.Gelisken F, Ziemssen F (2010) Diabetic maculopathy. Diagnosis and treatment. Ophthalmologe 107:773–786. doi:10.​1007/​s00347-010-2202-z CrossRef PubMed
  4.Chung EJ, Roh MI, Kwon OW, Koh HJ (2008) Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 28:957–963. doi:10.​1097/​IAE.​0b013e3181754209​ CrossRef PubMed
  5.Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I (2005) Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 123:1338–1343CrossRef PubMed
  6.Mansour AM, Schachat A, Bodiford G, Haymond R (1993) Foveal avascular zone in diabetes mellitus. Retina 13:125–128CrossRef PubMed
  7.Senanayake Pd, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, Miura S, Karnik S, Sears JE, Hollyfield JG (2007) Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 48:3301–3311CrossRef PubMed
  8.Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77:S93–S98CrossRef PubMed
  9.Shukla D, Kolluru CM, Singh J, John RK, Soman M, Gandhi B, Kim R, Perumalsamy N (2004) Macular ischaemia as a marker for nephropathy in diabetic retinopathy. Indian J Ophthalmol 52:205–210PubMed
  10.Xu J, Wei WB, Yuan MX et al (2012) Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina 32:322–329. doi:10.​1097/​IAE.​0b013e31821c4252​ CrossRef PubMed
  11.O’Hare P, Bilbous R, Mitchell T et al (2000) Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 23:1823–1829CrossRef PubMed
  12.Stefansson E (2006) Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51:364–380CrossRef PubMed
  13.Pournaras CJ, Miller JW, Gragoudas ES, Husain D, Munoz JL, Tolentino MJ, Kuroki M, Adamis AP (1997) Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol 115:1553–1558CrossRef PubMed
  14.Sharifipour F, Soheilian M, Idani E, Azarmina M, Yaseri M (2011) Oxygen therapy for diabetic macular ischemia: a pilot study. Retina 31:937–941. doi:10.​1097/​IAE.​0b013e3181f57e4d​ CrossRef PubMed
  15.Oguz H, Sobaci G (2008) The use of hyperbaric oxygen therapy in ophthalmology. Surv Ophthalmol 53:112–120. doi:10.​1016/​j.​survophthal.​2007.​12.​002 CrossRef PubMed
  16.Chang YH, Chen PL, Tai MC, Chen CH, Lu DW, Chen JT (2006) Hyperbaric oxygen therapy ameliorates the blood-retinal barrier breakdown in diabetic retinopathy. Clin Exp Ophthalmol 34:584–589CrossRef
  17.Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA (2004) Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 45:617–624CrossRef PubMed
  18.Kiryu J, Ogura Y (1996) Hyperbaric oxygen treatment for macular edema in retinal vein occlusion: relation to severity of retinal leakage. Ophthalmologica 210:168–170CrossRef PubMed
  19.Miyamoto H, Ogura Y, Wakano Y, Honda Y (1993) The long term results of hyperbaric oxygen treatment for macular edema with retinal vein occlusion. Nihon Ganka Gakkai Zasshi 97:1065–1069PubMed
  20.Haji SA, Frenkel RE (2010) Hyperbaric oxygen therapy for the treatment of radiation-induced macular ischemia. Clin Ophthalmol 4:433–436. doi:10.​2147/​OPTH.​S9803 CrossRef PubMed PubMedCentral
  21.Harris A, Arend O, Danis RP, Evans D, Wolf S, Martin BJ (1996) Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 80:209–213CrossRef PubMed PubMedCentral
  22.Pavlidis M, Stupp T, Georgalas I, Georgiadou E, Moschos M, Thanos S (2005) Multifocal electroretinography changes in the macula at high altitude: a report of three cases. Ophthalmologica 219:404–412CrossRef PubMed
  23.Atlas SA (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13:9–20PubMed
  24.Chua CC, Hamdy RC, Chua BH (1998) Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1401:187–190CrossRef PubMed
  25.Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, Honda Y (2003) Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44:393–402CrossRef PubMed
  26.Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP (1992) Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol 24:99–103PubMed
  27.UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720CrossRef PubMedCentral
  28.Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, Feener EP (2004) Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 47:113–123CrossRef PubMed
  29.Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86:311–315CrossRef PubMed PubMedCentral
  
• 作者单位：Farideh Sharifipour (1) (2)
  Mohammadreza Razzaghi (3)
  Alireza Ramezani (1) (3) (4)
  Mohsen Azarmina (1) (3)
  Mehdi Yaseri (5)
  Roham Soheilian (1)
  Masoud Soheilian (1) (3)
  
  1. Department of Ophthalmology and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., 16666, Tehran, Iran
  2. Department of Ophthalmology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  3. Negah Eye Hospital, Tehran, Iran
  4. Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Ophthalmology
  
• 出版者：Springer Netherlands
• ISSN：1573-2630

文摘

The purpose of this study was to evaluate the structural and functional effects of systemic oxygen therapy and enalapril in patients with diabetic macular ischemia (DMI). This randomized clinical trial consisted of 105 eyes with DMI divided into three groups. Group I received systemic oxygen by face mask at a flow rate of 10 L/min; Group II received 5 mg enalapril daily; and Group III received placebo tablets for 3 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography (OCT), extent of foveal avascular zone (FAZ) on fluorescein angiograms, and electroretinograms (ERG) were obtained at baseline and after 3 and 6 months. Overall, 102 patients completed the study. Baseline characteristics were not significantly different among groups. Significant improvement in BCVA and decrease in CMT and FAZ occurred at months 3 and 6 in oxygen group compared to deterioration in enalapril and control groups (All P values <0.001). ERG parameters were significantly better in oxygen group compared to enalapril group at months 3 and 6 and better than those in control group at month 3. Normobaric oxygen therapy for 3 months in DMI decreased CMT and FAZ and improved BCVA and ERG parameters. Enalapril did not show any favorable effect.